Drug profile · INN
dolutegravir sodium
TIVICAY
dolutegravir sodium (TIVICAY) is a human immunodeficiency virus type 1 integrase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — dolutegravir sodium
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
dolutegravir sodium (TIVICAY) is a human immunodeficiency virus type 1 integrase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Human immunodeficiency virus type 1 integrase inhibitor
Primary target: Human immunodeficiency virus type 1 integrase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| PMDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is dolutegravir sodium?
dolutegravir sodium (TIVICAY) is a human immunodeficiency virus type 1 integrase inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for dolutegravir sodium?
TIVICAY is a marketed brand name for dolutegravir sodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of dolutegravir sodium?
dolutegravir sodium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.